Hepatic Steatosis in Colorectal Cancer Patients on Chemotherapy
Author Information
Author(s): PD Peppercorn, RH Reznek, P Wilson, ML Slevin, RK Gupta
Primary Institution: St Bartholomew's Hospital
Hypothesis
What is the frequency and severity of fatty change of the liver in patients receiving 5-FU and folinic acid?
Conclusion
Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can complicate the assessment of liver metastases.
Supporting Evidence
- Forty-seven percent of patients developed hepatic steatosis during treatment.
- The mean fall in liver attenuation was 13.2 HU.
- Eleven patients had a change in liver attenuation of less than 10 HU.
- Overall, there was a significant difference in liver attenuation of all 21 patients before and after treatment.
Takeaway
Some cancer patients on a specific chemotherapy can develop fat in their liver, which can make it hard for doctors to see if the treatment is working.
Methodology
Twenty-seven patients were studied with CT scans before and after chemotherapy, and those with progressive disease were excluded.
Potential Biases
Potential bias in patient selection due to exclusion criteria.
Limitations
The study excluded patients with known causes of fatty liver and those with progressive disease, which may limit generalizability.
Participant Demographics
21 patients (11 male, 10 female, age 37-74 years).
Statistical Information
P-Value
0.0019
Statistical Significance
p=0.0019
Want to read the original?
Access the complete publication on the publisher's website